Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos (t) ide analogue therapy in chronic hepatitis B carriers
AA Shaheen, M AlMattooq, S Yazdanfar… - Alimentary …, 2017 - Wiley Online Library
Background Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are first‐line
treatments for chronic hepatitis B (CHB). Studies suggest lipid lowering effect of TDF in …
treatments for chronic hepatitis B (CHB). Studies suggest lipid lowering effect of TDF in …
[HTML][HTML] Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients
RM Lai, S Lin, MM Wang, N Li, JH Zhou… - World Journal of …, 2023 - ncbi.nlm.nih.gov
BACKGROUND Tenofovir alafenamide (TAF) has a serum lipid-raising effect in patients with
HIV; however, its effect on serum lipids and nonalcoholic fatty liver disease (NAFLD) risk in …
HIV; however, its effect on serum lipids and nonalcoholic fatty liver disease (NAFLD) risk in …
Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
EG Hwang, EA Jung, JJ Yoo, SG Kim, YS Kim - Hepatology International, 2023 - Springer
Background The aim of this study was to demonstrate how tenofovir alafenamide (TAF) and
other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B …
other hepatitis B treatment drugs differentially impact lipid profiles in chronic hepatitis B …
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis
J Jeong, JW Shin, SW Jung, EJ Park… - Clinical and Molecular …, 2021 - pmc.ncbi.nlm.nih.gov
Background/Aims Tenofovir alafenamide (TAF) has shown less favorable effect on lipids
compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding …
compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding …
Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
S Lin, W Huang, Z Liao, H Ma, W Wu, M Lin… - Scientific Reports, 2024 - nature.com
This study aimed to compare the serum lipid profiles between tenofovir disoproxil fumarate
(TDF) and tenofovir alafenamide (TAF) in the long-term treatment of chronic hepatitis B …
(TDF) and tenofovir alafenamide (TAF) in the long-term treatment of chronic hepatitis B …
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Background/Aims Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering
effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect …
effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect …
Tenofovir–disoproxil–fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection
K Suzuki, G Suda, Y Yamamoto, K Furuya… - Journal of …, 2021 - Springer
Background Entecavir and tenofovir–disoproxil–fumarate are first-line nucleos (t) ide
analogs (NA) for treatment of hepatitis B virus (HBV) infections; however, their long-term …
analogs (NA) for treatment of hepatitis B virus (HBV) infections; however, their long-term …
Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naïve chronic hepatitis B patients
K Koike, K Suyama, H Ito, H Itoh… - Hepatology …, 2018 - Wiley Online Library
Aim The study aimed to evaluate the efficacy and safety of tenofovir disoproxil fumarate
(TDF) and entecavir hydrate (ETV) in nucleos (t) ide analog (NA)‐naïve Japanese chronic …
(TDF) and entecavir hydrate (ETV) in nucleos (t) ide analog (NA)‐naïve Japanese chronic …
Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
PN Cheng, IC Feng, JJ Chen, HT Kuo… - Alimentary …, 2024 - Wiley Online Library
Background Lipid‐lowering effect was observed during treatment with tenofovir disoproxil
fumarate (TDF) for chronic hepatitis B (CHB). However, the metabolic features in patients …
fumarate (TDF) for chronic hepatitis B (CHB). However, the metabolic features in patients …
Three‐year efficacy and safety of tenofovir in nucleos (t) ide analog‐naïve and nucleos (t) ide analog‐experienced chronic hepatitis B patients
HM Wang, CH Hung, CM Lee, SN Lu… - Journal of …, 2016 - Wiley Online Library
Abstract Background and Aims: This study compared the efficacy and safety of tenofovir
disoproxil fumarate (TDF) up to 3 years of innucleos (t) ide analog (NA)‐naïve and NA …
disoproxil fumarate (TDF) up to 3 years of innucleos (t) ide analog (NA)‐naïve and NA …